Former US President Joe Biden, 82, has been diagnosed with prostate cancer, which has unfortunately spread to his bones. The ...

Watch the moon phases and libration for 2024, as seen from Earth's Southern Hemisphere, in this time-lapsed animation that is ...

Pfizer and Arvinas have axed two phase 3 trials from their estrogen receptor (ER) degrader R&D plan in the wake of mixed data. Arvinas disclosed the rethink alongside news that it is laying off ...

Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in adults, following robust data from the Phase III SELECT-GCA trial ...

Department of Materials Science and Engineering, University of California, Davis, Davis, California 95616, United States Biophysics Graduate Group, University of California, Davis, Davis, California ...

Pfizer has linked its PD-1 inhibitor to a 32% reduction in the risk of disease-related events in a phase 3 bladder cancer trial. But the study fell short of a clean sweep of positive outcomes ...

The country imported 65.9 GW of solar modules and cells last year. (Reuters) India added 25.3 gigawatt (GW) of solar module capacity and 11.6 GW of solar cell capacity in the year 2024 ...

State Key Laboratory of Microbial Metabolism, and School of Life Sciences & Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, PR China ...

Additionally, no interference with the CAR T-Cell Therapy was observed ... and determining the Recommended Phase 2 Dose (RP2D). “The safety and early efficacy data from the first dose cohort ...

Ake­so said its PD-1xVEGF bis­pe­cif­ic an­ti­body ivonescimab beat BeiGene’s PD-1 block­er Tevim­bra in a Phase 3 study in lung can­cer pa­tients in Chi­na.

Regulatory submissions are expected in 2026, and if approved, would be the second cell therapy for type 1 diabetes. Vertex Pharmaceuticals is conducting the pivotal phase 3 portion of a phase 1/2/3 ...